stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) EPS (diluted)
ACADIA Pharmaceuticals Inc.'s EPS (diluted) for fiscal 2025 was $2.30, up 69.1% from $1.36 in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.11. Over the past ten years it has ranged from −$2.36 (fiscal 2017) to $2.30 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. ACADIA Pharmaceuticals Inc. ranks 30th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $2.30 | 69.12% |
| FY2024 | $1.36 | — |
| FY2023 | −$0.37 | — |
| FY2022 | −$1.34 | — |
| FY2021 | −$1.05 | — |
| FY2020 | −$1.79 | — |
| FY2019 | −$1.60 | — |
| FY2018 | −$1.94 | — |
| FY2017 | −$2.36 | — |
| FY2016 | −$2.34 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.31 | 72.22% |
| Jun 2026 | $0.18 | 800.00% |
| Mar 2026 | $0.02 | (98.75%) |
| Dec 2025 | $1.60 | 280.95% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $2.11 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. compare | −$1.57 |
| DYN Dyne Therapeutics, Inc. compare | −$3.33 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| VKTX Viking Therapeutics, Inc. compare | −$5.40 |
| IRON Disc Medicine, Inc. compare | −$6.58 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ACAD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement